EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Salvage treatment incorporating arsenic trioxide for pediatric relapsed acute lymphoblastic leukemia: a retrospective real-world analysis

Jia-Nan Li, Ji-Xun Lin, Cui-Yun Yang, Ke Huang, Yan-Lai Tang, Li-Bin Huang, Jian Wang, Zhong Fan, Dan-Ping Huang, Li-Dan Zhang, Qiao-Ru Li, Zhi-Yong Ke und 3 weitere

Frontiers in Oncology · 09.11.2026 · 16

DOI: 10.3389/fonc.2026.1987372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 09.11.2026. Verfasst von Jia-Nan Li und 14 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Relapsed pediatric acute lymphoblastic leukemia (ALL) confers an unfavorable prognosis. We evaluated the outcomes of an arsenic trioxide (ATO)-incorporating chemotherapy protocol in pediatric first-relapsed ALL.

Methods

Patients were risk-stratified according to the ALL-REZ BFM 2002 protocol. Group A received an institutional ATO-containing protocol at one university-affiliated hospital between September 2010 and September 2021, while Group B followed the ALL-REZ BFM 2002 protocol at another one in the same city during the similar period.

Results

Group A comprised 43 patients, 9 high-risk, among whom one (11.1%) underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Group B had 35 patients with 15 high-risk among whom 7 (46.7%) received allo-HSCT. In non-high-risk patients, 5-year event-free survival (EFS) was comparable between groups (73.5% vs 70.0%, P = 0.794). Among high-risk patients, EFS was higher in Group A (44.4% vs 13.3%, P = 0.048). Moreover, Group A remained independently associated with better EFS in a multivariable Cox model incorporating allo-HSCT as a time-dependent covariate (HR = 0.50, 95% CI: 0.25-0.99, P = 0.048).

Conclusion

High-risk relapsed ALL stratified by the ALL-REZ BFM 2002 stratification system carries a poor prognosis. The incorporation of ATO into salvage regimens merits further investigation, and prospective randomized controlled trials would help confirm its promising prognostic advantages.

Zitieren

APA

Li, J., Lin, J., Yang, C., Huang, K., Tang, Y., Huang, L., Wang, J., Fan, Z., Huang, D., Zhang, L., Li, Q., Ke, Z., Zhou, D., Xue, H., & Luo, X. (2026). Salvage treatment incorporating arsenic trioxide for pediatric relapsed acute lymphoblastic leukemia: a retrospective real-world analysis. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1987372

Vancouver

Li J, Lin J, Yang C, Huang K, Tang Y, Huang L, et al. Salvage treatment incorporating arsenic trioxide for pediatric relapsed acute lymphoblastic leukemia: a retrospective real-world analysis. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1987372

BibTeX
@article{Li2026,
  author = {Li, Jia-Nan and Lin, Ji-Xun and Yang, Cui-Yun and Huang, Ke and Tang, Yan-Lai and Huang, Li-Bin and Wang, Jian and Fan, Zhong and Huang, Dan-Ping and Zhang, Li-Dan and Li, Qiao-Ru and Ke, Zhi-Yong and Zhou, Dun-Hua and Xue, Hong-Man and Luo, Xue-Qun},
  title = {Salvage treatment incorporating arsenic trioxide for pediatric relapsed acute lymphoblastic leukemia: a retrospective real-world analysis},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1987372}
}
Kostenlos starten →